Plat-refractory mUC pts have no therapies that significantly extend OS, which is
Pts who had progressed during/following plat received 1200 mg atezo IV q3w and could continue treatment past RECIST v1.1 PD until loss of clinical benefit. Co-primary endpoints were confirmed RECIST v1.1 ORR (central review) and immune-modified RECIST ORR (per investigator). PD-L1 status on immune cells (IC) was scored centrally (SP142 IHC assay): IC2/3, 1, 0.
310 pts (median 66 y) were evaluable: 78% had visceral mets; 43% had ≥ 2 prior mUC regimens. RECIST v1.1 ORR was 28% in IC2/3 pts (95% CI: 19, 38), 19% (14, 25) in IC1/2/3 and 16% (12, 20) in all pts. Both CRs (15% in IC2/3; 9% in IC1/2/3; 7% in all pts) and PRs occurred in pts with poor prognostic factors and were durable (71% ongoing at the 14 Mar 2016 data cut off). mDOR was not reached with a 17.5-mo mFU (range, 0.2 + -21.1). Among 134 pts continuing treatment post PD, 19% had subsequent ≥ 30% decrease in target lesions. 1-y OS was 50% in IC2/3 pts (95% CI: 40, 60), 40% (33, 47) in IC1/2/3 and 37% (31, 42) overall, with 30% of all pts alive. Overall and subgroup mOS are in the Table. Atezo remained well tolerated with low rates of immune-mediated AEs and discontinuations. 70% of pts had a related AE (mostly fatigue [31%]; nausea [14%]), 16% were G3-4 (no G5 events). > 1-y safety, biomarker correlates of OS (immune gene expression, mutation load) and TCGA classification will be presented.
Median OS in IMvigor210a Cohort 2 Subgroups
|Subgroup||n||mo||95% CI||n||mo||95% CI||n||mo||95% CI|
|All||100||11.9||9.0, 17.9||207||9.0||7.1, 10.9||310||7.9||6.7, 9.3|
|Prior regimens for mUC|
|0||24||8.5||3.9, NE||42||9.5||5.7, 12.8||58||9.5||5.9, 15.5|
|1||34||NE||10.9, NE||79||10.9||8.0, 13.3||120||9.0||7.2, 11.3|
|2||20||17.0||2.8, NE||43||6.2||3.1, 17.8||66||5.9||3.3, 8.7|
|3||12||8.7||5.0, 16.5||26||6.6||4.5, 10.2||42||6.4||3.8, 10.2|
|≥4||10||13.8||2.7, NE||17||8.0||2.5, 17.9||24||7.4||4.6, 11.1|
|Bellmunt risk factors:b|
|0||31||NE||17.1, NE||61||NE||17.8, NE||83||NE||17.1, NE|
|1||35||11.9||5.1, NE||72||8.3||5.1, 13.3||117||6.8||5.4, 10.3|
|2||28||9.0||2.5, 11.4||59||5.1||2.9, 8.0||89||5.0||3.1, 6.5|
|3||6||5.3||2.8, 7.2||15||3.4||2.8, 5.7||21||3.4||2.1, 5.0|
|Primary tumor site|
|Upper tract||18||10.9||7.4, NE||42||8.3||5.1, 11.4||69||7.6||5.0, 10.5|
|Bladder||79||12.8||7.2, NE||160||9.0||6.7, 11.4||233||7.9||6.4, 9.6|
|Lymph node only||24||17.7||9.3, NE||39||17.8||9.3, NE||43||17.8||9.3, NE|
|Visceral||66||9.9||6.2, 16.5||152||7.3||5.8, 9.5||243||7.0||5.9, 8.1|
a Study ID NCT02108652. b Defined as baseline ECOG PS ≥ 1, liver metastasis, and/or hemoglobin
Heavily pre-treated mUC pts on atezo monotherapy had durable responses, with encouraging OS. Combined with favorable safety, atezo may transform treatment of plat-treated mUC. A randomized Ph III study vs chemo in this population is ongoing (NCT02302807).
Clinical trial identification
Legal entity responsible for the study
F. Hoffmann-La Roche Ltd
F. Hoffmann-La Roche Ltd
Y. Loriot: grants and personal fees from Sanofi, personal fees from Roche, Astellas, Jannsen, Ipsen. Personal fees from BMS, from null, outside the submitted work. J.E. Rosenberg: Non-financial support and other from Roche-Genetech, personal fees from Agensys, Eli Lilly, Merck, Sanofi, Oncogenex. T.B. Powles: Honoraria: Roche, BMS, Merck. Research Funding: Roche, AstraZeneca. A. Necchi: personal fees from Roche, grants and personal fees from Merck Sharp & Dohme. I. Duran: Cnsulting/advisory: Jansen, Roche, Amgen, Novartis, Pierre fabre. Travel, Accomdations: Astellas. C. Theodore: Travel and accommodation expenses from Novartis, Sanofi. J.L. Perez-Gracia: Grant from Roche. A. Thåström, B. Danner, S. Mariathasan, O. Abidoye: Employee and shareholder of Genentech, Inc. M. van der Heijden: Roche/Genentech - Reimbursement for patient care and data management of study subjects. advisory board: Roche/GenentechAstellas, Astra Zeneca. Astellas - Research grant. All other authors have declared no conflicts of interest.
Resources from the same session
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and can only be disabled by changing your browser preferences.